Top Story

Lenalidomide–dexamethasone extended PFS, OS in transplant-ineligible multiple myeloma

September 22, 2014

Continuous lenalidomide plus low-dose dexamethasone significantly extended PFS compared with melphalan, prednisone and thalidomide in patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, according to phase 3 study results.

Results of an interim analysis showed the combination of lenalidomide (Revlimid, Celgene) and dexamethasone also demonstrated a trend toward improved OS.

figure In the Journals

As-needed rituximab controlled follicular lymphoma with less treatment

September 18, 2014
A retreatment strategy that utilized rituximab as needed was associated with similar disease control as maintenance rituximab yet required less treatment for patients…
In the Journals

Para-aortic irradiation increased diabetes risk in long-term survivors of Hodgkin’s lymphoma

September 17, 2014
Radiation to para-aortic lymph nodes was associated with a dose-dependent increased risk for diabetes among 5-year survivors of Hodgkin’s lymphoma, according to…
Health Care Updates

Health of Ground Zero first responders in jeopardy if Zadroga Act expires

September 11, 2014
First responders continue to be diagnosed with cancer more than a decade after the tragedy that took place on Sept. 11. In 2016, however, the legislation that currently…
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

figure In the Journals

Lenalidomide–dexamethasone extended PFS, OS in transplant-ineligible multiple myeloma

September 22, 2014
Continuous lenalidomide plus low-dose dexamethasone significantly extended PFS compared with melphalan, prednisone and thalidomide in patients with…
figure In the Journals

As-needed rituximab controlled follicular lymphoma with less treatment

September 18, 2014
A retreatment strategy that utilized rituximab as needed was associated with similar disease control as maintenance rituximab yet required less…
In the Journals

Para-aortic irradiation increased diabetes risk in long-term survivors of Hodgkin’s lymphoma

September 17, 2014
Radiation to para-aortic lymph nodes was associated with a dose-dependent increased risk for diabetes among 5-year survivors of Hodgkin’s…
Health Care Updates

Health of Ground Zero first responders in jeopardy if Zadroga Act expires

September 11, 2014
First responders continue to be diagnosed with cancer more than a decade after the tragedy that took place on Sept. 11. In 2016, however, the…
figure Meeting News Coverage

Toxins at Ground Zero linked with cancer among thousands of first responders

September 11, 2014
The tragedy of Sept. 11, 2001 still haunts Americans in countless ways, with many survivors continuing to struggle with the enduring grief and trauma…
figure Cover Story Publication Exclusive

Cancer treatment during pregnancy ‘a constant balancing act’

HemOnc Today, September 10, 2014
Cancer during pregnancy traditionally has been a rare phenomenon.Through the last third of the 20th century, about 1 in 1,000 pregnant women…
figure In the Journals

Combination of ibrutinib, rituximab induced responses in high-risk CLL

September 3, 2014
Patients with high-risk chronic lymphocytic leukemia demonstrated encouraging rates of objective response and durable remission after treatment with…
figure Editorial Publication Exclusive

The changing face of our major meetings: Evolution or revolution?

HemOnc Today, September 10, 2014
John Sweetenham, MD, PhD
One morning in late July, I was poised over my laptop at exactly 9 a.m. Mountain time, ready for the ASH Annual Meeting and Exposition registration…
figure In the Journals Perspective

HLA-matched donors available for most HSCT candidates

HemOnc Today, September 10, 2014
A majority of hematopoietic stem-cell transplantation candidates who do not have related donors have suitable adult donors or cord-blood units…
Industry News

Growth estimated in B-cell NHL treatment market value

August 30, 2014
The market value of B-cell non-Hodgkin’s lymphoma treatments will experience moderate growth across six major markets from $4.59 billion in…
More Headlines »